Participated · Series B · Sep 2021

accuRx offers a collaborative communications platform that brings patients and their healthcare teams together, beginning with the National Health Service (NHS) in the UK. The software is used by 98% of GP practices in England and by a growing number of hospitals and community trusts. The company’s product enables existing health and care systems to deliver technology-enabled care and to improve communication between clinicians and patients. Leadership is led by CEO Jacob Haddad and CTO Laurence Bargery. The newly raised funds are intended to grow the team, enhance accuRx’s offering to GP practices and build products to enable expansion into secondary care. Accurx's core product is Chain SMS, a messaging app used by doctor surgeries to communicate with patients. Chain SMS supports nurses, administrative staff, practice managers and GPs for tasks such as sending advice, notifying normal results, and appointment reminders, with all communication saved back to patients' medical records. The company originally built datasets and tools to reduce inappropriate antibiotic use but pivoted to a broader clinical communication platform while keeping data and machine learning central to its approach. Chain SMS launched in February 2018 and is already in use by 20% of GP practices in England, up from close to zero at launch. Accurx was founded by Jacob Haddad and Laurence Bargery at Entrepreneur First in 2016 and remains focused on improving healthcare delivery through tighter patient-team communication. Financially, the company has just closed an £8.8M Series A led by Atomico.

Led · Series C · Apr 2019

SigTuple develops smart robotic microscopes and AI software for automating clinical laboratory workflows, with its flagship product AI100 focused on digital haematology. The company has concentrated on AI100 since 2020 and counts major diagnostics players among its customers. AI100 received US FDA 510(k) clearance in September 2023, making SigTuple the first Indian company and the third worldwide to secure FDA clearance for AI-assisted digital haematology. SigTuple uses Horiba Medical as a distribution channel in South Asia and has expanded into Southeast Asia, the Middle East, and North Africa, with plans to enter Europe and the Americas. The company will use the new funding to support regulatory clearances, broaden its product offering, and accelerate geographic expansion. To date the company has raised more than $40 million and is gaining significant traction in the Indian market. SigTuple develops AI and digitization solutions for pathology, primarily automating analysis of peripheral blood smears and urine samples and offering the product AI100 in India. The company says it is expanding its AI suite toward Hematology, Cytology, and Microbiology to become a one‑stop shop for lab AI. Over the past 12 months SigTuple reports major product improvements, new product additions, stronger customer traction, and beefed up channel partners. It has forged partnerships with large diagnostic chains and hospitals including HCG Hospitals, Krsnaa Diagnostics, and Thyrocare Technologies. Management plans to use new capital to drive geographical expansion, broaden the product portfolio, and support regulatory clearances. The CEO, Tathagato Rai Dastidar, stated that 2023 is the year SigTuple will go global with expansions planned across SEA, MENA, North America, and Europe. SigTuple is a diagnostics startup based in India. The company announced it secured a $16-million Series C round. The Series C was led by Trusted Insight. Existing investors Accel Partners, Chiratae Ventures and Pi Ventures participated in the round. Flipkart co-founder Binny Bansal also participated and will join SigTuple's board as part of the agreement. The company made the announcement on Monday; no further operational or financial details were provided in the article. SigTuple develops AI and machine-learning solutions to analyze vital biological samples and assist diagnosis, and it also produces low-cost smart hardware for pathological analysis. The company emphasizes making diagnostics more accessible, affordable and accurate through smart technology. With the latest funding, SigTuple plans to expand distribution, conduct additional R&D, and broaden deployment of its solutions across markets in India. Investors and company leadership frame its work as part of a broader big-data driven shift in healthcare delivery. Financially, SigTuple announced a $19 million Series B that brings its total capital raised to nearly $25 million. Prior financings included a Series A in February 2017 and a seed round in 2015. SigTuple Technologies Pvt. Ltd. is a Bengaluru-based health technology startup. The article reports the company raised $5.8 million in a Series A round. The round was led by existing investor Accel Partners. The company announced the funding in a statement on Monday. No further details on product offerings, use of proceeds, other investors, or operating metrics were disclosed in the article. The firm is structured as a private limited company (Pvt. Ltd.).

Participated · Debt Financing · Jul 2018

Proportunity is a UK-focused fintech founded in 2018 by Romanian founders that uses proprietary AI/ML to identify relatively cheap real estate with strong price-growth potential. The company offers mortgages with a 5% deposit to help first-time buyers and young families access homeownership. Its AI selects properties it predicts will appreciate, and the business has grown rapidly—clientele grew 200% year-on-year. Proportunity has helped clients purchase over EUR 117M of real estate and financed almost EUR 47M of purchases in 2022 (a 152% improvement versus the prior period). The startup plans to develop new products to cement its UK position, including mortgages with a 0% deposit and a rent-to-own offering, with launches targeted as soon as this year. Proportunity provides home purchase equity loans that let buyers purchase with a 5% deposit by offering an equity loan of up to £150,000 or 25% of the house price. That equity loan sits on top of a mainstream mortgage (up to 4.5x income), meaning customers can effectively borrow up to six times their income. The company says it uses machine learning to identify fair-valued homes in high-potential growth areas, which it argues de-risks lending and reduces the need for large deposits. Proportunity plans to use new funding to grow its team and increase its maximum loan size from £90,000 to £150,000 per home. The startup cites that some 85% of U.K. renters want to own a home but are blocked by high deposit requirements and rising house prices. Main competitors named in the article include Generation Home and Wayhome (aka Unmortgage). Proportunity is a London-based startup that provides deposit-boosting equity loans of up to £90,000, enabling buyers to complete purchases with only a 5% cash deposit. The company says it is the only 5% LTV lender in the UK, according to CEO and co-founder Vadim Toader. It recently secured a debt capital injection of up to £7.5 million from Conister Bank and others to manage record demand following Britain’s post-lockdown housing boom. Proportunity’s portfolio has expanded rapidly, doubling over the past two years in just the last two months. To support further growth the company has hired Marita Cavalcanti as CFO, launched a new intermediaries platform for mortgage brokers, and joined Tech Nation’s fintech cohort. The facility is intended to allow Proportunity to keep up with demand and continue issuing loans while other lenders pulled back. Proportunity provides 'Help to Buy'-style equity loans of up to 15% of a property's value to help primarily first-time buyers increase their effective deposit and secure more competitive mortgages. Borrowers pay monthly interest from the start and must repay the equity loan at 15% of the current market price on sale or remortgage (within five years), so repayments track house-price movements. The company uses machine learning-based forecasting that combines data such as crime, school ratings, broadband speeds and pollution to identify good-value properties and reduce risk. Proportunity says it has helped more than 20 and fewer than 100 homes and currently works with 12 mortgage brokers; two of the U.K.'s top-five high-street lenders have co-lent on multiple homes. The team has built partnerships with real estate agencies and their mortgage-broker arms to generate referrals of first-time buyers. Founded in 2016 by Vadim Toader and Stefan Boronea, the company remains focused on scaling its lending model and distribution partnerships in the U.K. Proportunity is a London-based startup and Entrepreneur First alumnus that uses machine learning to forecast future house prices and identify high-growth areas. It is FCA-authorised as a mortgage lender and plans to offer equity loans of up to 15% of a property's price to boost buyers' deposits. Proportunity's model combines its forecasts with property selection and then provides interest-only equity loans repayable after five years at 15% of the current market price. The company says combined monthly repayments will be lower than taking a 95% mortgage and, unlike shared ownership schemes, borrowers do not pay rent on the equity portion. To begin lending it has secured £5 million in credit and has raised £2.7 million in funding to bring the equity loans to market and further develop its price-forecasting technology. Backers named in the funding include Global Founders Capital, Concrete VC (backed by Starwood Capital Group), Savills, Entrepreneur First, Trusted Insights, Le Studio VC, and angels including Matt Robinson, Chris Mairs, Charlie Songhurst, Nicolas Berggruen and Julian Critchlow. Half the Proportunity team, including CEO Vadim Toader, are taking out a Proportunity loan to test the product themselves.